Radioimmunoassay and Biomarkers Core

放射免疫分析和生物标记物核心建议继续提供越来越多的高- 为糖尿病研究中心(DRC)不断发展的团队提供优质的免疫分析和生化服务， 翻译和临床科学家。上一个周期的服务包括放射免疫分析(RIA)， 酶联免疫吸附试验(ELISA)，Luminex平台上的多重ELISA，高效液体 在ThermoFisher平台上进行色谱分析，在黄泉仪器上进行代谢物分析 (YSI)平台，以及最近在Ella平台上针对不断扩大的各种糖尿病和 来自血液、尿液、唾液和组织样本的代谢相关激素、细胞因子和代谢物。 事实证明，这些化验服务对刚果民主共和国和宾夕法尼亚大学糖尿病研究所的当前研究至关重要， 肥胖与代谢(IDOM)，并将继续是未来运作和发展的一个组成部分 中心和研究所。在下一个周期中，RIA/Biomarkers核心将继续现有的免疫分析服务 包括对高样本数实验的成本可行性至关重要的RIA，以及扩展服务 除了RIA、ELISA、Luminex、HPLC和YSI平台之外，还包括开发更灵敏的 基于微流控酶联免疫吸附试验(ELLA)的多重平台。将使用ELLA技术来实现精准 细胞因子的多重作用具有更高的敏感性和理解所需的扩展动态范围 在啮齿动物和人类研究中炎症和新陈代谢的交集，因此提高了我们的 扩大对刚果民主共和国调查人员的化验服务。此外，核心将积极参与与 糖尿病、肥胖和新陈代谢研究人员的本地研究社区，同时提高 所提供的化验服务。此外，RIA/Biomarkers核心将整合新的和现有的 通过斯米洛中心内的共享资源为不断扩大的调查人员提供化验服务 翻译研究。核心位于IDOM的12层，靠近胰岛细胞 生物学、功能基因组学和啮齿动物代谢表型核心促进密切相互作用 这些DRC核心。核心提供的化验服务的综合交付将得到进一步加强 利用iLab开发用于订购、跟踪、计费和交付服务的信息基础设施。这个 在中央核心设施而不是在分散的地点执行大量区域影响评估和评估 整个大学在设备、人力和用品方面提供了显著的总体节省 我们的调查人员，同时重要的是允许生成更高质量的结果，因为我们增强了 质量控制/质量保证/质量管理(QA/QC/QM)过程。我们将继续合作 与NIH赞助的其他核心资源和宾夕法尼亚大学医学院合作，以加强和扩大 为我们的调查人员提供的服务数量，提高了提供服务的效率和技术专长 ，并继续提高我们的吞吐量和数据质量。

The Radioimmunoassay and Biomarkers Core proposes to continue offering an increasing number of high- quality immunoassay and biochemistry services to our evolving group of Diabetes Research Center (DRC) basic, translational, and clinical scientists. Services over the last cycle have included radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), multiplex ELISA on the Luminex platform, high performance liquid chromatography (HPLC) on the ThermoFisher platform, metabolite assays on the Yellow Springs Instruments (YSI) platform, and most recently multiplex ELISA on the ELLA platform for an expanding variety of diabetes and metabolism related hormones, cytokines, and metabolites derived from blood, urine, salivary and tissue samples. These assay services have proven essential for current research in the DRC and Penn’s Institute for Diabetes, Obesity & Metabolism (IDOM) and will remain an integral part of the future operation and development of the Center and Institute. In the next cycle the RIA/Biomarkers Core will continue existing immunoassay serives including RIA that are essential for cost feasibility of high sample number experiments, and expand services beyond RIA, ELISA, Luminex, HPLC, and YSI platforms to include development of assays on a more sensitive multiplex platform based on microfluidic ELISA (ELLA). ELLA technology will be used to implement accurate multiplexing of cytokines with enhanced sensitivity and an expanded dynamic range required for understanding the intersection of inflammation and metabolism in rodent and human studies, and so enhance the value of our expanding assay services for DRC investigators. In addition, the Core will proactively engage in outreach to the local research community of diabetes, obesity and metabolism investigators, while enhancing the QA/QC/QM of the assay services provided. In addition, the RIA/Biomarkers Core will integrate delivery of new and existing assay services to an expanding base of investigators via shared resources within the Smilow Center for Translational Research. The Core is located on the 12th floor in IDOM and in near proximity to the Islet Cell Biology, Functional Genomics, and Rodent Metabolic Phenotyping Cores that fosters close interactions among these DRC Cores. The integrated delivery of assay services provided by the Core will be enhanced by further development of informatics infrastructure for ordering, tracking, billing and delivery of service using iLab. The performance of a large number of RIAs and ELISAs in a central core facility rather than in scattered locations throughout the University provides a significant overall savings in equipment, personnel effort, and supplies for our investigators, while importantly allowing for the generation of results with better quality due to our enhanced quality control/quality assurance/quality management (QA/QC/QM) processes. We will continue collaborations with other NIH-sponsored core resources and the School of Medicine at Penn in order to enhance and expand the number of services available to our investigators, increase efficiency and technical expertise in the provision of assay services, and continue to improve our throughput and data quality.